1U5 Stock Overview
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Wave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.60 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$3.28 |
| Beta | -1.21 |
| 11 Month Change | 0% |
| 3 Month Change | 176.42% |
| 1 Year Change | 176.42% |
| 33 Year Change | 274.76% |
| 5 Year Change | -53.74% |
| Change since IPO | -61.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1U5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -5.0% | -1.3% |
| 1Y | 176.4% | -22.0% | 7.4% |
Return vs Industry: 1U5 exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 1U5 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 1U5 volatility | |
|---|---|
| 1U5 Average Weekly Movement | 25.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1U5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1U5's weekly volatility has increased from 16% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 267 | Paul B. Bolno | www.wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).
Wave Life Sciences Ltd. Fundamentals Summary
| 1U5 fundamental statistics | |
|---|---|
| Market cap | €2.10b |
| Earnings (TTM) | -€136.86m |
| Revenue (TTM) | €51.48m |
40.6x
P/S Ratio-15.3x
P/E RatioIs 1U5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1U5 income statement (TTM) | |
|---|---|
| Revenue | US$53.61m |
| Cost of Revenue | US$149.11m |
| Gross Profit | -US$95.50m |
| Other Expenses | US$47.02m |
| Earnings | -US$142.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | -178.14% |
| Net Profit Margin | -265.84% |
| Debt/Equity Ratio | 0% |
How did 1U5 perform over the long term?
See historical performance and comparison